MET and non-small cell lung carcinoma: Recently, amivantamab, an EGFR-MET bispecific antibody with immune cell-directing activity demonstrated a response rate of 40% with good tolerability in pretreated patients with NSCLC harboring EGFR exon 20 insertions.60